NCT01190410 - Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 27, 2017

Study Completion Date

November 27, 2017

Conditions

Crohn's Disease

Interventions

DRUG

certolizumab pegol

400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg

DRUG

certolizumab pegol

200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to \< 40 kg

Trial Locations (10)

114, Orange

111, Aurora

103, Atlanta

116, Atlanta

112, Shreveport

104, Baltimore

126, Morristown

301, Parkville

203, Edmonton

204, Hamilton